In 2023, the antibacterial medicine sales in Australia stood at USD 11.0 PPP Per Capita. The forecast data from 2024 to 2028 indicates a steady year-on-year growth. From 2023 to 2024, sales are expected to rise by 0.91%. The forecasted year-on-year variations show incremental increases: 0.90% from 2024 to 2025, 0.89% from 2025 to 2026, 1.77% from 2026 to 2027, and 0.87% from 2027 to 2028. Over the last two years (2026 to 2028), the average yearly growth rate (CAGR) is 1.18%. This consistent growth suggests stability and sustained demand in the Australian market for antibacterial medicine.
Key future trends to watch for include emerging bacterial resistance, new antibacterial innovations, healthcare policy changes, and the impact of global pharmaceutical market dynamics on local sales. Monitoring these factors will be crucial for understanding the future trajectory of antibacterial medicine sales in Australia.
